Dr Reddy's Russian woes take a new turn - Views on News from Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Dr Reddy's Russian woes take a new turn

Nov 15, 1999

The introduction of product patents in India may be still sometime away but other countries such as Russia are paying more heed to the World Trade Organisation rulings. Pfizer, it has been reported, has successfully sued Dr Reddy's for selling a heart ailment product, which is similar to its own product in Russia. The Indian company has claimed that the product has been manufactured by an entirely different process. Dr Reddy's is one of the fastest growing companies in the pharmaceutical sector having a 1.4% market share in domestic formulations. The company has developed from being a purely bulk drug based company to a formulation-based company. The company is one of the leading spenders on R&D (5% of FY99 sales) in India.

Indian companies have over the years developed skills in reverse engineering, which permits them to copy and legally sell (India permits only process patents) such products in various markets. However, with the latest ruling in Russia, other Indian companies selling reverse engineered products may find themselves in the soup. In effect, the compliance date for the WTO guidelines seems to have been brought forward in the Russian markets.

For Dr Reddy's the problem is one of few already existing with regards to its Russian operations. Earlier, the company lost heavily on account of the melt down in the Russian economy. The company's poor performance in the second quarter of the current year has been attributed to problems pertaining to the Russian operations. With the company having lost its rights to sell its heart ailment product, revenues will further deteriorate. It is now likely that the company's Russian operations will put downward pressure on revenue and bottomline growth in the coming quarters.

Market View:
Analysts are increasingly getting convinced of the seriousness of the R&D efforts of the company. They are recommending a 'BUY' as they expect the R&D efforts to yield returns for the company in the future.

Equitymaster requests your view! Post a comment on "Dr Reddy's Russian woes take a new turn". Click here!

  

More Views on News

Sorry! There are no related views on news for this company/sector.

Most Popular

India: Recovery Stalled by Vaccine Games? (The Honest Truth)

Apr 13, 2021

Ajit Dayal on how India's vaccine strategy will impact the markets.

A Stock with 700% Return Potential Comes with Additional Payoffs (Profit Hunter)

Apr 15, 2021

Narayana Murthy was one of the first unicorn founders to get the backing of this entity...

11x Bankruptcy to Bluechip Stock: A Rare India Revival Story (Profit Hunter)

Apr 16, 2021

There is no stopping this 11-bagger stock from significant upside.

Top 3 Nifty ETFs to Buy Now (Fast Profits Daily)

Apr 20, 2021

In this video I tell you the three Nifty ETFs I think are the best.

Why Did the Market Crash on Monday? (Fast Profits Daily)

Apr 13, 2021

In this video, I'll you what I think is the real reason behind yesterday's market crash.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

DR. REDDYS LAB SHARE PRICE


Apr 20, 2021 (Close)

TRACK DR. REDDYS LAB

  • Track your investment in DR. REDDYS LAB with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

DR. REDDYS LAB 5-YR ANALYSIS

COMPARE DR. REDDYS LAB WITH

MARKET STATS